Quarterly ResultJun 9, 2026, 04:51 PM
Regenerative Medical Q1 Net Loss $(876K) on $2.64M Revenue
AI Summary
Regenerative Medical Technology Group Inc. reported a significant increase in revenue to $2.64 million for the first quarter of 2026, up from $1.36 million in the prior year. Despite higher gross profit, the company's net loss widened to $(876,274) from $(760,039) due to a substantial increase in interest expense. The company continues to face significant financial challenges, with an accumulated deficit of over $76 million and a working capital deficit of over $36 million, raising substantial doubt about its ability to continue as a going concern.
Key Highlights
- Revenue increased to $2,639,353 for Q1 2026, up from $1,364,341 in Q1 2025.
- Net loss widened to $(876,274) in Q1 2026, compared to $(760,039) in Q1 2025.
- Net loss per common share was $(0.07) for Q1 2026, up from $(0.06) in Q1 2025.
- Gross profit rose to $1,766,491 in Q1 2026 from $943,894 in Q1 2025.
- Interest expense significantly increased to $(2,190,549) in Q1 2026 from $(895,850) in Q1 2025.
- Accumulated deficit reached $(76,241,785) and working capital deficit was $(36,639,004) as of March 31, 2026.
- Cash and cash equivalents increased to $1,061,448 as of March 31, 2026, from $956,718 at December 31, 2025.
- The company's ability to continue as a going concern is in substantial doubt due to accumulated and working capital deficits.
Price Impact
More from RMTG